NEW YORK (GenomeWeb News) - Genizon today said it has raised CA$10 million ($8.5 million) in series D equity financing from Pfizer and Dutch venture capital company BTF.
Pfizer’s investment is related to a licensing agreement it signed with Genizon in mid-January. At the time, Genizon said that Pfizer had taken an equity stake in the firm, but it did not disclose the amount of the investment.
CFO Henry Bretecher told GenomeWeb News that the breakdown in investment was "roughly half and half" between Pfizer and BTF.
BTF has been an investor in Genizon, formerly called Galileo Genomics, since 2001, when it participated in a $16.5 million financing round. BTF also participated in the company’s $5.2 million round in 2003.